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The possibility in recent years that chronic infection with
Chlamydia pneumoniae (CPn) may represent a risk factor for
atherosclerosis or a mechanism of rapid progression of
ischemic heart disease, or both, has attracted the attention
of investigators and clinicians all over the world. After the
first description of a seroepidemiologic association between
antibody titers against the intracellular bacterium CPn and
coronary artery disease in 1988 (1), scientific publications
(2) from both sides of the Atlantic have confirmed the initial
observations. However, more recent reports, one from the
U.S. (3) and another from the United Kingdom (4), have
cast doubts as to the existence of a true association between
CPn seropositivity and coronary events. In contrast, two
other large studies also reported this year have found a
strong association between immunoglobulin G (IgG) anti-
bodies against CPn and stroke (5) and between anti–CPn
IgA antibodies and mortality from ischemic heart disease
(6). Thus, at present, controversy exists regarding the
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postulated relation between CPn seropositivity and ischemic
heart disease. One of the possible explanations for the
controversial findings may be that in defining “seropositiv-
ity,” different authors have used different serologic tech-
niques or have looked at different antibodies, or both. At
least three different methods have been used to assess
anti–CPn antibody titers—enzyme-linked immunosorbent
assay (ELISA), the complement fixation technique and the
microimmunofluorescence (MIF) test, which measures spe-
cific immunoglobulins (i.e., IgG, IgA and IgM).
Limitations of serology to assess active CPn infection.
Although serology constitutes an important diagnostic tool
for the assessment of chronic CPn infection, it is not
without limitations. Even the MIF test, which has been
considered by some (7) to be the “gold standard” test for
assessment of CPn infection owing to its reportedly high
sensitivity and specificity, has some drawbacks, including
the unknown reproducibility of the technique and the need
for highly skilled operators. In addition to the intrinsic
limitations of serologic tests, the issue is further complicated
by the fact that different investigators have used different
antigens or CPn strains and have applied diverse criteria for
the definition of chronic versus acute CPn infection. Some
of the studies have looked only at IgG or IgA and others
have based their conclusions on the presence or absence of
circulating immune complexes containing the CPn lipo-
polysaccharide. The selection of control individuals also
varied among studies and earlier reports, in particular, failed
to control for confounding factors such as conventional risk
factors of coronary disease and social class. There are also
other considerations, such as the high prevalence of sero-
positive cases found in the general population, and this is
probably a reflection of the incidence of infection and the
duration of raised antibody titers after infection. It is
therefore difficult to establish whether seropositivity to CPn
indicates a chronic, active infection or simply reflects past
exposure. In some patients high antibody titers against CPn
may indicate past exposure to the microorganism and not
necessarily the need for treatment. In other patients, how-
ever, high antibody titers may be the expression of active
CPn infection, which may trigger inflammatory mecha-
nisms and contribute to atheromatous plaque disruption.
Accurate diagnosis of active infection should require re-
peated samples to demonstrate rising antibody titers.
Thus, although seroepidemiologic studies have undoubt-
edly helped to identify an intriguing and potentially impor-
tant association between CPn infection and atheromatous
disease, more accurate techniques are required to character-
ize active CPn infection in the search for the true role of this
organism in ischemic heart disease.
CPn detection in atheromatous tissue—the role of mac-
rophages. Studies have shown that CPn can be detected in
atheromatous vessels using techniques such as immunohis-
tochemistry, cell culture and polymerase chain reaction
(PCR). Muhlestein et al. (8) have observed that .70% of
coronary atherectomy samples obtained from individuals
with documented coronary artery disease contained CPn.
Importantly, only 4% of specimens obtained from individ-
uals without coronary atheroma showed the presence of the
microorganism. These observations have been confirmed
and expanded by studies carried out by Maass et al. (9) in
Germany, who examined coronary artery specimens in 70
patients who underwent elective or urgent myocardial re-
vascularization for management of their coronary artery
disease. Segments from the same atherosclerotic lesions
were cultured and also subjected to nested PCR for the
assessment of CPn genomic deoxyribonucleic acid (DNA).
Viable CPn was cultured from 16% of the 70 atheromatous
samples, and CPn DNA was formed in 30% of the samples.
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Department of Cardiological Sciences, St. George’s Hospital Medical
School, London, United Kingdom.
Journal of the American College of Cardiology Vol. 34, No. 5, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00400-3
CPn was not found in 17 tissue specimens without ather-
oma. The DNA sequencing of PCR products revealed no
differences between the coronary isolates and respiratory
reference strains. This finding confirms previous observa-
tions in experimental animal models and indicates that from
the respiratory tract, CPn gains access to the circulation
carried by alveolar macrophages and subsequently lodges in
diseased vascular tissue. The alveolar macrophage thus
appears to act both as a reservoir and a carrier for CPn.
Recent in vitro studies (10) have shown that peripheral
blood mononuclear cells infected with CPn express CPn
messenger ribonucleic acid three days after infection and
also induce a lymphocyte proliferative response for up to
seven days, suggesting that CPn remains metabolically
active within monocytes. CPn infection activates macro-
phages, which in turn produce inflammatory cytokines and
metalloproteinases, which may contribute to atheromatous
plaque disruption. However, whether CPn plays a causal
role in both atherogenesis and progression of coronary
artery disease remains a controversial issue. Studies in
animals have suggested a possible etiologic role for CPn in
the development of neointimal atherosclerotic changes (11).
In patients with ischemic heart disease, macrolide antibiotic
trials have reported a reduction in the incidence of serious
cardiac events (12,13) and reduction of antibody titers to
CPn (12,14), but these findings were not confirmed by
other studies (15).
Viable CPn and coronary artery disease. The finding of
Wong et al. (16) reported in this issue of the Journal (16)
that “circulating” CPn DNA is more commonly found in
men with coronary artery disease than in those without
coronary atheroma contributes to the debate regarding the
role of CPn infection in ischemic heart disease. The
presence of bacterial DNA is likely to represent active
infection as previously documented in animal studies and
clinical reports.
Only a small proportion of patients (,10%) in Wong’s
study had CPn DNA in their blood mononuclear cells. A
much larger proportion of patients, however, tested sero-
positive for CPn. As previously observed in other studies
(9), Wong et al. found no correlation between anti–CPn
antibody titers and positive PCR results. However, a trend
was observed for seropositive subjects to have a higher
prevalence of CPn DNA in their circulating monocytes. It
is conceivable that the relatively small number of patients
showing CPn DNA may account for the lack of statistical
significance regarding this finding.
Wong et al. (16) correctly argued that their method may
provide a more accurate detection of active CPn infection
than serology, as it is difficult at present to equate positive
serology with active chronic infection. This is likely to be
due to the fact that no agreed serologic criteria exist to
define active infection, and also to the fact that more often
than not studies have based their assessment on single
serologic measurements as opposed to repeated measure-
ments.
The study by Wong et al. (16), like others previously
using different methods for the detection of CPn, has shown
a positive association between this infectious agent and
coronary artery disease. Although no causality can be
inferred from the observations in this study, findings in
Wong’s report are of interest because they show a relation
between viable CPn and the presence of coronary atheroma.
The present study is also important because it may set up
the basis for well-designed investigations to assess whether
antibiotic treatment can affect the load of circulating CPn
DNA and result in improved patient outcome. Future
studies may use this observation to ascertain what propor-
tion of those patients showing circulating CPn DNA
develop atheromatous lesions over time and to establish the
true sensitivity and specificity of the test used by Wong et al.
In addition, and as discussed by Wong et al., repeated
testing will be necessary to determine the reproducibility of
their PCR findings. The prevalence of circulating DNA
may vary in the individual patient over time, and it would
therefore be important to carry out repeated measurements
with and without intervention to assess changes in the rate
of circulating intracellular CPn.
The intriguing finding that men but not women showed
an association between circulating CPn DNA and coronary
artery disease requires further investigation. Although this
observation may be just the result of the lack of statistical
power in this study, owing to the small number of women,
it may also represent a differential response of women to
CPn infection. Acute-phase reactants and inflammatory
cytokines are under the modulation of estrogen, and studies
have shown differential levels of inflammatory markers in
men versus women. Thus, studies should be designed to
address this question specifically.
Wong et al. (16) are probably right to speculate that the
presence of circulating DNA, as assessed in their study, may
identify patients with active infection who may benefit from
antibiotic treatment. However, further studies should be
carried out before findings in this observational report can
be systematically used for patient risk stratification or to
decide which patients are more likely to benefit from
antibiotic intervention. We concur with Wong et al. (16)
that it is likely that certain patients are more likely than
others to benefit from antibacterial therapy, but this has to
be objectively demonstrated. Whether the detection of
circulating DNA by PCR, as proposed in this study,
represents the test of choice to identify patients who will
derive benefit from antibiotic treatment needs to be inves-
tigated.
At present there is no conclusive evidence that chronic
infection with CPn may lead to ischemic heart disease and
that antibiotic therapy should be used in patients with
coronary artery disease. However, clinical observations such
as those made by Wong et al. (16), together with available
clinical and experimental evidence, should represent a stim-
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ulus to continue the search for a causal link between chronic
CPn infection and cardiovascular disease.
The intriguing and challenging hypothesis that CPn may
play a role in atherogenesis or rapid coronary artery disease
progression, or both, is attractive and clearly deserves further
investigation. Although in our view large, well-designed
antibiotic eradication trials are important, major efforts and
funding should be directed to the identification of specific
patient subsets in whom the hypothesized pathogenic
mechanisms are more likely to operate and in whom the
proposed therapeutic intervention is more likely to succeed.
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